|
| 1,3,5-Trihydroxy-4-prenylxanthone Basic information |
Product Name: | 1,3,5-Trihydroxy-4-prenylxanthone | Synonyms: | 1,3,5-Trihydroxy-4-prenylxanthone;1,3,5-Trihydroxy-4-(3-Methylbut-2-en-1-yl)-9H-xanthen-9-one;9H-Xanthen-9-one, 1,3,5-trihydroxy-4-(3-methyl-2-buten-1-yl)-;1,3,5-Trihydroxy-4-(3-methyl-2-buten-1-yl)-9H-xanthen-9-one;5-Trihydroxy-4-prenylxanthone;1,3,5Trihydroxy4prenylxanthone,1,3,5 Trihydroxy 4 prenylxanthone | CAS: | 53377-61-0 | MF: | C18H16O5 | MW: | 312.32 | EINECS: | | Product Categories: | | Mol File: | 53377-61-0.mol | |
| 1,3,5-Trihydroxy-4-prenylxanthone Chemical Properties |
solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | form | powder | color | Yellow |
| 1,3,5-Trihydroxy-4-prenylxanthone Usage And Synthesis |
Description | 1,3,5-Trihydroxy-4-prenylxanthone is a relatively potent inhibitor of phosphodiesterase type 5 (PDE5), with an IC50 value of 3.0 μM.
1,3,5-Trihydroxy-4-prenylxanthone inhibits LPS-induced NF-κB and AP-1 activations by interfering with the posttranslational modification (phosphorylation and/or ubiquitinylation) of IRAK-1 in the cell membrane to impede TAK1-mediated activation of IKK and MAPKs signal transduction.
3. 1,3,5-Trihydroxy-4-prenylxanthone shows in vitro inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 56.3plusmn;0.4 and 46.0plusmn;0.3 M, respectively. | target | NF-kB | IkB | AP-1 | JNK | ERK | TGF-β/Smad | AChR | IKK |
| 1,3,5-Trihydroxy-4-prenylxanthone Preparation Products And Raw materials |
|